Latest 10-K annual reports

NASDAQ
Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy receives a new FDA PDUFA target action date of August 22, 2026, following positive Phase 3 HOPE-3 trial results and a resubmission addressing a prior Complete Response Letter.
NASDAQ
Silexion Therapeutics Corp reports significant losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead oncology candidate, SIL204, towards Phase 2/3 clinical trials.
OTC.Pink
Vireo Growth Inc. reports a significant 170% revenue increase in 2025 driven by strategic mergers, despite incurring net losses, as it navigates a complex and evolving cannabis market.
NASDAQ
Auburn National Bancorporation reported a 13.4% increase in net earnings to $7.3 million for 2025, driven by improved net interest income and margin, while maintaining robust capital ratios.
NASDAQ
AXT, Inc. reports a net loss for 2025 amid significant revenue decline and trade restrictions, while securing $100 million in new capital to fund InP substrate expansion.
OQB
Crimson Wine Group, Ltd. reported a significant decrease in net sales and operating income for fiscal year 2025, driven by challenging market conditions and a goodwill impairment charge, despite a strategic acquisition post-year-end.
NASDAQ
Brilliant Earth Group, Inc. reported a net loss of $6.4 million for 2025, a significant decline from the prior year's net income, despite a 3.6% increase in net sales to $437.5 million.
NASDAQ
GitLab Inc. announced robust 26% revenue growth to $955.2 million for fiscal year 2026, alongside a significant shift to positive operating cash flow and adjusted free cash flow, despite an increased net loss.
OID
Ankam, Inc. reported a significant increase in revenue and a reduced net loss for fiscal year 2025, driven by Asian market expansion, despite ongoing going concern issues and material weaknesses in internal controls.
NASDAQ
Lululemon Athletica Inc. reports 5% net revenue growth in 2025, driven by strong international performance, despite a decline in Americas sales and a significant impact from increased tariffs.
NASDAQ
Fold Holdings, a bitcoin-focused financial services company, reported a 34% increase in net revenue for 2025, but also a significant rise in operating and net losses, alongside new product launches and debt restructuring.
NASDAQ
NextNav Inc. reported a significant increase in net losses and a decrease in revenue for fiscal year 2025, as it continues to invest heavily in its NextGen 5G positioning, navigation, and timing solutions and seeks critical FCC approvals.
NASDAQ
IZEA Worldwide, Inc. reported net income of $42,326 for the fiscal year ended December 31, 2025, marking a significant turnaround from a $18.85 million net loss in 2024, driven by strategic cost reductions and a focus on core enterprise customers.
NASDAQ
Farmers National Banc Corp. filed an amendment to its 2025 Annual Report on Form 10-K to include its policy on recovery of erroneously awarded compensation.
NASDAQ
HealthEquity, Inc. announced robust financial results for the fiscal year ended January 31, 2026, driven by significant increases in HSA assets and net income, alongside strategic technology investments and operational efficiencies.
NYSE
BlackSky Technology Inc. reported a 4.4% revenue increase to $106.6 million for fiscal year 2025, driven by strong mission solutions, but saw net losses widen to $70.3 million and Adjusted EBITDA decline significantly.
NASDAQ
Gossamer Bio announced a workforce reduction and missed the primary endpoint in its Phase 3 PROSERA trial for seralutinib, leading to strategic re-evaluation and a need for additional capital.
NASDAQ
Academy Sports and Outdoors reported a 2.0% net sales increase to $6.05 billion for fiscal year 2025, but saw a 1.5% decline in comparable sales and a 10.0% drop in net income.
NASDAQ
Longeveron Inc. reported a widened net loss for fiscal year 2025 and substantial doubt about its ability to continue as a going concern, despite advancing its lead product candidate, laromestrocel, in multiple clinical programs.
Kalaris Therapeutics, a clinical-stage biopharmaceutical company, reported significant net losses in 2025 while advancing its lead product candidate, TH103, for retinal diseases with promising early clinical data.
NYSE
The Mosaic Company filed an amendment to its 2025 annual report to include omitted shareholder data and a revised consent for its Esterhazy Potash Facility.
OTC.Pink
Idaho Copper Corporation reported continued net losses and a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite progress on its CuMo Project exploration permits.
NYSE
Gap Inc. reported a 2% increase in net sales to $15.4 billion for fiscal 2025, alongside a slight decline in net income and diluted EPS, as it continues strategic transformation amidst a challenging macroeconomic environment.
Groovy Company's 2025 Annual Report details significant progress on its OTCM Protocol blockchain platform, despite ongoing financial challenges and a need for substantial capital.
OID
MGT Capital Investments, Inc. has ceased active cryptocurrency mining and hosting operations, sold its primary facility, and is now evaluating strategic alternatives amidst significant going concern uncertainties.
NASDAQ
Comstock Holding Companies, Inc. announced significant revenue and net income growth for fiscal year 2025, driven by managed portfolio expansion and strategic investments.
NASDAQ
Lifeway Foods, Inc. announced a significant increase in net sales and net income for fiscal year 2025, alongside key corporate governance changes and strategic investments.
NASDAQ
Expion360 Inc. reported a 71.6% increase in net sales for 2025, reaching $9.7 million, despite continued net losses and an ongoing 'going concern' qualification from auditors.
NASDAQ
Lake Shore Bancorp, Inc. reported a significant increase in net income and improved asset quality for 2025, following its successful second-step conversion and strategic focus on commercial lending and core deposit growth.
NASDAQ
Neuronetics, Inc. announced significant revenue growth for 2025, driven by the Greenbrook acquisition, alongside a new CEO appointment and ongoing efforts to improve profitability.